Contact

All Stories

  1. Transmembrane protein 14A protects glomerular filtration barrier integrity

    Article • Physiological Reports, December 2023, Wiley

    Professor Pancras C.W. Hogendoorn

  2. Immunological factors linked to geographical variation in vaccine responses

    Article • Nature Reviews Immunology, September 2023, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  3. Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective

    Article • Cancers, August 2023, MDPI AG

    Professor Pancras C.W. Hogendoorn

  4. Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective

    Article • July 2023, MDPI AG

    Professor Pancras C.W. Hogendoorn

  5. Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone

    Article • Cancers, September 2022, MDPI AG

    Professor Pancras C.W. Hogendoorn

  6. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases

    Article • Annals of Diagnostic Pathology, April 2022, Elsevier

    Professor Pancras C.W. Hogendoorn

  7. Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis

    Article • Cancers, October 2021, MDPI AG

    Professor Pancras C.W. Hogendoorn

  8. NTRK fusions are extremely rare in bone tumours

    Article • Histopathology, September 2021, Wiley

    Professor Pancras C.W. Hogendoorn

  9. The adapter protein Myd88 plays an important role in limiting mycobacterial growth in a zebrafish model for tuberculosis

    Article • Virchows Archiv, February 2021, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  10. Co-existence of lung carcinoma metastasis and enchondroma in the femur of a patient with Ollier disease

    Article • Virchows Archiv, October 2020, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  11. Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas

    Article • Journal of Bone and Joint Surgery, August 2020, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  12. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma

    Article • Virchows Archiv, November 2019, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  13. Nikolay Ivanovich Pirogov (1810–1881): Anatomical research to develop surgery

    Article • Clinical Anatomy, November 2019, Wiley

    Professor Pancras C.W. Hogendoorn

  14. Glomerular permeability is not affected by heparan sulfate glycosaminoglycan deficiency in zebrafish embryos

    Article • AJP Renal Physiology, November 2019, American Physiological Society

    Professor Pancras C.W. Hogendoorn

  15. Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy

    Article • JMIR Research Protocols, September 2019, JMIR Publications Inc.

    Professor Pancras C.W. Hogendoorn

  16. Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma

    Article • BMJ Open, May 2019, BMJ

    Professor Pancras C.W. Hogendoorn

  17. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

    Article • The Oncologist, April 2019, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  18. Non‐ossifying fibroma: A RAS‐MAPK driven benign bone neoplasm

    Article • The Journal of Pathology, March 2019, Wiley

    Professor Pancras C.W. Hogendoorn

  19. A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup

    Article • Cancer Chemotherapy and Pharmacology, March 2019, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  20. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Article • European Journal of Cancer, March 2019, Elsevier

    Professor Pancras C.W. Hogendoorn

  21. New indicators and indexes for benchmarking university–industry–government innovation in medical and life science clusters: results from the European FP7 Regions of Knowledge HealthTIES project

    Article • Health Research Policy and Systems, January 2019, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  22. Women in healthcare in Imperial Russia: The contribution of the surgeon Nikolay I Pirogov

    Article • Journal of Medical Biography, January 2019, SAGE Publications

    Professor Pancras C.W. Hogendoorn

  23. Conjunctival Leiomyosarcoma, a Rare Neoplasm Always Originating at the Limbus? Report of a New Case and Review of 11 Published Cases

    Article • Ocular Oncology and Pathology, January 2019, Karger Publishers

    Professor Pancras C.W. Hogendoorn

  24. M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma

    Article • Virchows Archiv, December 2018, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  25. Increased dynamin expression precedes proteinuria in glomerular disease

    Article • The Journal of Pathology, November 2018, Wiley

    Professor Pancras C.W. Hogendoorn

  26. Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma

    Article • Journal of Surgical Oncology, September 2018, Wiley

    Dr. CFM Sier, Professor Pancras C.W. Hogendoorn

  27. Bioorthogonally Applicable Fluorescence Deactivation Strategy for Receptor Kinetics Study and Theranostic Pretargeting Approaches

    Article • ChemBioChem, July 2018, Wiley

    Professor Pancras C.W. Hogendoorn

  28. The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study

    Article • Virchows Archiv, January 2018, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  29. BCRP expression in schwannoma, plexiform neurofibroma and MPNST

    Article • Oncotarget, September 2017, Impact Journals, LLC

    Professor Pancras C.W. Hogendoorn

  30. Hematopoietic Tumors Primarily Presenting in Bone

    Article • Surgical Pathology Clinics, September 2017, Elsevier

    Professor Pancras C.W. Hogendoorn

  31. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma

    Article • BMC Cancer, May 2017, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  32. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal...

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  33. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study

    Article • Acta Oncologica, April 2017, Taylor & Francis

    Professor Pancras C.W. Hogendoorn

  34. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review

    Article • Critical Reviews in Oncology/Hematology, February 2017, Elsevier

    Professor Pancras C.W. Hogendoorn

  35. High prevalence of autoimmune disease in the rare inflammatory bone disorder sternocostoclavicular hyperostosis: survey of a Dutch cohort

    Article • Orphanet Journal of Rare Diseases, January 2017, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  36. MRI appearances of atypical cartilaginous tumour/grade I chondrosarcoma after treatment by curettage, phenolisation and allografting

    Article • The Bone & Joint Journal, December 2016, Bone & Joint

    Professor Pancras C.W. Hogendoorn

  37. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Article • The Lancet Oncology, October 2016, Elsevier

    Dr. Heike Elisabeth Daldrup-Link, Professor Pancras C.W. Hogendoorn

  38. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy

    Article • Cancer Immunology Immunotherapy, July 2016, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  39. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival

    Article • Modern Pathology, June 2016, Elsevier

    Professor Pancras C.W. Hogendoorn

  40. CXCR4 signaling is controlled by immobilization at the plasma membrane

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, April 2016, Elsevier

    Professor Pancras C.W. Hogendoorn

  41. Nikolay Ivanovich Pirogov (1810–1881): A pioneering Russian surgeon and medical scientist

    Article • Journal of Medical Biography, March 2016, SAGE Publications

    Professor Pancras C.W. Hogendoorn

  42. Automation of Technology for Cancer Research

    Article • January 2016, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  43. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway

    Article • European Journal of Cancer, January 2016, Elsevier

    Professor Pancras C.W. Hogendoorn

  44. A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization

    Article • Cancer Genetics, November 2015, Elsevier

    Professor Pancras C.W. Hogendoorn

  45. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients

    Article • European Journal of Cancer, November 2015, Elsevier

    Professor Pancras C.W. Hogendoorn

  46. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors

    Article • Oncotarget, October 2015, Impact Journals, LLC

    Professor Pancras C.W. Hogendoorn

  47. Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes

    Article • International Journal of Molecular Sciences, July 2015, MDPI AG

    Professor Pancras C.W. Hogendoorn

  48. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Resp...

    Article • Journal of Clinical Oncology, July 2015, American Society of Clinical Oncology (ASCO)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  49. Chemotherapy in osteosarcoma

    Article • The Journal of Pathology, March 2015, Wiley

    Professor Pancras C.W. Hogendoorn

  50. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype

    Article • Histopathology, March 2015, Wiley

    Professor Pancras C.W. Hogendoorn

  51. Neoadjuvant denosumab for extensive giant cell tumor in os ischium —a case report

    Article • Acta Orthopaedica, February 2015, Acta Dermato-Venereologica

    Professor Pancras C.W. Hogendoorn

  52. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

    Article • Annals of Oncology, December 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  53. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

    Article • Annals of Oncology, November 2014, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  54. Nikolay Ivanovich Pirogov: a surgeon's contribution to military and civilian anaesthesia

    Article • Anaesthesia, November 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  55. De novodiscovery of phenotypic intratumour heterogeneity using imaging mass spectrometry

    Article • The Journal of Pathology, November 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  56. Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis

    Article • Virchows Archiv, October 2014, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  57. Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis

    Article • PLoS ONE, September 2014, PLOS

    Professor Pancras C.W. Hogendoorn

  58. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53

    Article • The Journal of Pathology, June 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  59. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

    Article • Cancer, May 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  60. Molecular genetics of chondroid tumours

    Article • Diagnostic Histopathology, May 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  61. The Clinical Approach Toward Giant Cell Tumor of Bone

    Article • The Oncologist, April 2014, Alphamed Press

    Lizz van der Heijden, Professor Pancras C.W. Hogendoorn

  62. Primary intraosseous manifestation of Rosai-Dorfman disease: 2 cases and review of literature

    Article • Journal of the Belgian Society of Radiology, March 2014, Ubiquity Press, Ltd.

    Professor Pancras C.W. Hogendoorn

  63. Transactivating mutation of theMYOD1gene is a frequent event in adult spindle cell rhabdomyosarcoma

    Article • The Journal of Pathology, January 2014, Wiley

    Professor Pancras C.W. Hogendoorn

  64. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogen...

    Article • European Journal of Cancer, January 2014, Elsevier

    Professor Pancras C.W. Hogendoorn

  65. Frequent truncating mutations of STAG2 in bladder cancer

    Article • Nature Genetics, October 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  66. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998)

    Article • Annals of Oncology, October 2013, Elsevier

    Professor Pancras C.W. Hogendoorn

  67. CD99-positive undifferentiated round cell sarcoma diagnosed on fine needle aspiration cytology, later found to harbour aCIC-DUX4translocation: a recently described entity

    Article • Cytopathology, July 2013, Wiley

    Professor Pancras C.W. Hogendoorn

  68. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma

    Article • BMC Cancer, May 2013, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  69. FXR regulates CETP

    Article • Journal of Lipid Research, April 2013, American Society for Biochemistry & Molecular Biology (ASBMB)

    thierry claudel, Professor Pancras C.W. Hogendoorn

  70. Imaging Mass Spectrometry-based Molecular Histology Differentiates Microscopically Identical and Heterogeneous Tumors

    Article • Journal of Proteome Research, March 2013, American Chemical Society (ACS)

    Professor Pancras C.W. Hogendoorn

  71. Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor

    Article • International Journal of Cancer, March 2013, Wiley

    Professor Pancras C.W. Hogendoorn

  72. Tumor-Associated Macrophages Are Related to Volumetric Growth of Vestibular Schwannomas

    Article • Otology & Neurotology, February 2013, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  73. Inactivation of Patched1 in Mice Leads to Development of Gastrointestinal Stromal-Like Tumors That Express Pdgfrα but Not Kit

    Article • Gastroenterology, January 2013, Elsevier

    Professor Pancras C.W. Hogendoorn

  74. Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas

    Article • Virchows Archiv, December 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  75. Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup

    Article • Virchows Archiv, December 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  76. The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma

    Article • European Journal of Cancer, December 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  77. Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma

    Article • PLoS ONE, November 2012, PLOS

    Professor Pancras C.W. Hogendoorn

  78. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

    Article • The Lancet Oncology, October 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  79. High frequency of MYC gene amplification is a common feature of radiation‐induced sarcomas. Further results from EORTC STBSG TL 01/01

    Article • Genes Chromosomes and Cancer, September 2012, Wiley

    Professor Pancras C.W. Hogendoorn

  80. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone

    Article • BMC Cancer, August 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  81. Imaging mass spectrometry statistical analysis

    Article • Journal of Proteomics, August 2012, Elsevier

    Professor Pancras C.W. Hogendoorn

  82. A multidisciplinary approach to giant cell tumors of tendon sheath and synovium—A critical appraisal of literature and treatment proposal

    Article • Journal of Surgical Oncology, July 2012, Wiley

    Lizz van der Heijden, Professor Pancras C.W. Hogendoorn

  83. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma

    Article • Modern Pathology, July 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  84. Low-Grade Chondrosarcoma of Long Bones Treated with Intralesional Curettage Followed by Application of Phenol, Ethanol, and Bone-Grafting

    Article • Journal of Bone and Joint Surgery, July 2012, The Journal of Bone and Joint Surgery, Inc.

    Professor Pancras C.W. Hogendoorn

  85. The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis)

    Article • The Bone & Joint Journal, June 2012, Bone & Joint

    Lizz van der Heijden, Professor Pancras C.W. Hogendoorn

  86. Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas

    Article • Virchows Archiv, May 2012, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  87. An osteosarcoma zebrafish model implicates Mmp‐19 and Ets‐1 as well as reduced host immune response in angiogenesis and migration

    Article • The Journal of Pathology, March 2012, Wiley

    Professor Pancras C.W. Hogendoorn

  88. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

    Article • European Journal of Cancer, March 2012, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  89. Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma

    Article • Clinical Cancer Research, January 2012, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  90. The First European Interdisciplinary Ewing Sarcoma Research Summit

    Article • Frontiers in Oncology, January 2012, Frontiers

    Professor Pancras C.W. Hogendoorn

  91. Osteosarcoma Models: From Cell Lines to Zebrafish

    Article • Sarcoma, January 2012, Hindawi Publishing Corporation

    Professor Pancras C.W. Hogendoorn

  92. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter

    Article • The Journal of Pathology, November 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  93. Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data

    Article • Genes Chromosomes and Cancer, October 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  94. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials

    Article • Annals of Oncology, October 2011, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  95. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma

    Article • Oncogene, August 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  96. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT

    Article • Oncogene, August 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  97. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease

    Article • Laboratory Investigation, August 2011, Elsevier

    Professor Pancras C.W. Hogendoorn

  98. Breakpoint characterization of large deletions in EXT1 or EXT2 in 10 Multiple Osteochondromas families

    Article • BMC Medical Genetics, June 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  99. A short-term in vivo model for giant cell tumor of bone

    Article • BMC Cancer, June 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  100. IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis

    Article • PLoS ONE, May 2011, PLOS

    Professor Pancras C.W. Hogendoorn

  101. Maffucci syndrome: A genome‐wide analysis using high resolution single nucleotide polymorphism and expression arrays on four cases

    Article • Genes Chromosomes and Cancer, May 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  102. The immunophenotype of osteoclasts and macrophage polykaryons

    Article • Journal of Clinical Pathology, May 2011, BMJ

    Professor Pancras C.W. Hogendoorn

  103. Growth plate regulation and osteochondroma formation: insights from tracing proteoglycans in zebrafish models and human cartilage

    Article • The Journal of Pathology, April 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  104. Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia

    Article • Virchows Archiv, April 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  105. Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

    Article • Clinical Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  106. Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials

    Article • European Journal of Cancer, April 2011, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  107. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

    Article • Cancer Immunology Immunotherapy, January 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  108. Cartilage ultrastructure in proteoglycan‐deficient zebrafish mutants brings to light new candidate genes for human skeletal disorders

    Article • The Journal of Pathology, January 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  109. Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples

    Article • BMC Research Notes, January 2011, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  110. Distinct histological features characterize primary angiosarcoma of bone

    Article • Histopathology, January 2011, Wiley

    Professor Pancras C.W. Hogendoorn

  111. Late sarcoma development after curettage and bone grafting of benign bone tumors

    Article • European Journal of Radiology, January 2011, Elsevier

    Professor Pancras C.W. Hogendoorn

  112. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression

    Article • The Journal of Pathology, December 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  113. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target

    Article • The Journal of Pathology, December 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  114. Tiling resolution array-CGH shows that somatic mosaic deletion of the EXT gene is causative in EXT gene mutation negative multiple osteochondromas patients

    Article • Human Mutation, December 2010, Hindawi Publishing Corporation

    Professor Pancras C.W. Hogendoorn

  115. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional‐based study

    Article • The Journal of Pathology, November 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  116. Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone

    Article • Journal of Clinical Pathology, October 2010, BMJ

    Professor Pancras C.W. Hogendoorn

  117. No Haploinsufficiency but Loss of Heterozygosity for EXT in Multiple Osteochondromas

    Article • American Journal Of Pathology, October 2010, Elsevier

    Professor Marcel Karperien, Professor Pancras C.W. Hogendoorn

  118. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option

    Article • Molecular Cancer, September 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  119. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma

    Article • Oncogene, September 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  120. Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma

    Article • Cancer Research, September 2010, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  121. Heterogeneous and Complex Rearrangements of Chromosome Arm 6q in Chondromyxoid Fibroma

    Article • American Journal Of Pathology, September 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  122. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone

    Article • BMC Cancer, August 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  123. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma

    Article • Genes Chromosomes and Cancer, August 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  124. Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma

    Article • Journal of Cellular Physiology, August 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  125. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours

    Article • Histopathology, August 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  126. Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma

    Article • Laboratory Investigation, July 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  127. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets

    Article • Nature Reviews Cancer, June 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  128. A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone

    Article • The American Journal of Surgical Pathology, June 2010, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  129. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  130. Impact of EWS-ETS Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-E.W.I.N.G. 99 Trial

    Article • Journal of Clinical Oncology, April 2010, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  131. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours

    Article • Histopathology, March 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  132. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell–macrophage lineage

    Article • Immunological Reviews, February 2010, Wiley

    Professor Pancras C.W. Hogendoorn

  133. Soft tissue sarcomas: introduction to the Virchows Archiv review issue

    Article • Virchows Archiv, February 2010, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  134. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors

    Article • International Journal of Cancer, January 2010, Wiley

    Prof. Dr. Sjoerd H van der Burg, Professor Pancras C.W. Hogendoorn

  135. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

    Article • European Journal of Cancer, January 2010, Elsevier

    Professor Pancras C.W. Hogendoorn

  136. Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: A population-based study

    Article • European Journal of Surgical Oncology, December 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  137. Sdhd and Sdhd/H19 Knockout Mice Do Not Develop Paraganglioma or Pheochromocytoma

    Article • PLoS ONE, November 2009, PLOS

    Professor Pancras C.W. Hogendoorn

  138. Genome‐wide transcriptome analyses reveal p53 inactivation mediated loss of miR‐34a expression in malignant peripheral nerve sheath tumours

    Article • The Journal of Pathology, November 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  139. Prognostic factors in pulmonary metastasized high‐grade osteosarcoma

    Article • Pediatric Blood & Cancer, November 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  140. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways

    Article • British Journal of Cancer, November 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  141. Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes

    Article • Modern Pathology, November 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  142. The Journal of Pathology 2008 Jeremy Jass Prize for Research Excellence in Pathology

    Article • The Journal of Pathology, October 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  143. Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas

    Article • Journal of Thoracic Oncology, October 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  144. Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort

    Article • Genes Chromosomes and Cancer, September 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  145. Molecular pathology of sarcomas: concepts and clinical implications

    Article • Virchows Archiv, September 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  146. Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma

    Article • The Journal of Pathology, September 2009, Wiley

    Professor Marcel Karperien, Professor Pancras C.W. Hogendoorn

  147. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro

    Article • Journal of Cellular and Molecular Medicine, September 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  148. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2

    Article • The Journal of Pathology, August 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  149. Running GAGs: myxoid matrix in tumor pathology revisited

    Article • Virchows Archiv, August 2009, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  150. Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment

    Article • Cancer Research, July 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  151. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix

    Article • Journal of Cellular and Molecular Medicine, July 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  152. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Article • Cancer Research, July 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  153. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition

    Article • The Journal of Pathology, June 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  154. Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors

    Article • Clinical Cancer Research, April 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  155. Extra‐abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature

    Article • Journal of Cutaneous Pathology, March 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  156. The molecular and cellular basis of exostosis formation in hereditary multiple exostoses

    Article • International Journal of Experimental Pathology, March 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  157. The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to Oncology

    Article • Clinical Cancer Research, March 2009, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  158. Aberrant Heparan Sulfate Proteoglycan Localization, Despite Normal Exostosin, in Central Chondrosarcoma

    Article • American Journal Of Pathology, March 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  159. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program

    Article • Gynecologic Oncology, March 2009, Elsevier

    Professor Pancras C.W. Hogendoorn

  160. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array‐CGH analysis

    Article • Genes Chromosomes and Cancer, February 2009, Wiley

    Professor Pancras C.W. Hogendoorn

  161. Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors

    Article • The American Journal of Surgical Pathology, January 2009, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  162. CD33+ CD14− Phenotype Is Characteristic of Multinuclear Osteoclast‐Like Cells in Giant Cell Tumor of Bone

    Article • Journal of Bone and Mineral Research, January 2009, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  163. Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes

    Article • Journal of Internal Medicine, November 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  164. The cytotoxic effect of phenol and ethanol on the chondrosarcoma-derived cell line OUMS-27: AN IN VITRO EXPERIMENT

    Article • Journal of Bone and Joint Surgery - British Volume, November 2008, Bone & Joint

    Professor Pancras C.W. Hogendoorn

  165. Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group

    Article • European Journal of Cancer, November 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  166. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways

    Article • Molecular Immunology, September 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  167. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate

    Article • European Journal of Cancer, September 2008, Elsevier

    Professor Pancras C.W. Hogendoorn

  168. Results of Diagnostic Review in Pediatric Bone Tumors and Tumorlike Lesions

    Article • Journal of Pediatric Orthopaedics, July 2008, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  169. The Clinical Approach Towards Chondrosarcoma

    Article • The Oncologist, May 2008, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  170. A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens

    Article • The Oncologist, April 2008, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  171. The Clinical Approach Towards Chondrosarcoma

    Article • The Oncologist, March 2008, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  172. Myxoid tumours of soft tissue: the so‐called myxoid extracellular matrix is heterogeneous in composition

    Article • Histopathology, February 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  173. Telomere biology in giant cell tumour of bone

    Article • The Journal of Pathology, February 2008, Wiley

    Professor Pancras C.W. Hogendoorn

  174. Incidence of Biopsy-Proven Bone Tumors in Children

    Article • Journal of Pediatric Orthopaedics, January 2008, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  175. EWSR1-CREB1 and EWSR1-ATF1 Fusion Genes in Angiomatoid Fibrous Histiocytoma

    Article • Clinical Cancer Research, December 2007, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  176. CT‐guided, COBRA‐FISH‐assisted diagnosis of well‐differentiated liposarcoma (inflammatory subtype) of the retroperitoneum

    Article • Histopathology, August 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  177. Increased HIF1α in SDH and FH deficient tumors does not cause microsatellite instability

    Article • International Journal of Cancer, July 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  178. Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

    Article • Journal of Clinical Oncology, July 2007, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  179. Does parosteal liposarcoma differ from other atypical lipomatous tumors/well-differentiated liposarcomas? A molecular cytogenetic study using combined multicolor COBRA-FISH karyotyping and array-based comparative genomic hybridization

    Article • Cancer Genetics and Cytogenetics, July 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  180. The role of noncartilage‐specific molecules in differentiation of cartilaginous tumors

    Article • Cancer, June 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  181. MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance

    Article • Skeletal Radiology, June 2007, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  182. Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi

    Article • European Journal of Nuclear Medicine and Molecular Imaging, June 2007, Springer Science + Business Media

    Dr. Mick Welling, Professor Pancras C.W. Hogendoorn

  183. The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions

    Article • JNCI Journal of the National Cancer Institute, March 2007, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  184. Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity

    Article • Arthritis & Rheumatism, January 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  185. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup

    Article • JNCI Journal of the National Cancer Institute, January 2007, Oxford University Press (OUP)

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  186. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas

    Article • The Journal of Pathology, January 2007, Wiley

    Professor Pancras C.W. Hogendoorn

  187. Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma

    Article • Cancer Genetics and Cytogenetics, January 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  188. Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways

    Article • Clinical Cancer Research, January 2007, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  189. Basic fibroblast growth factor and fibroblastic growth factor receptor–1 may contribute to head and neck paraganglioma development by an autocrine or paracrine mechanism

    Article • Human Pathology, January 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  190. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

    Article • European Journal of Cancer, January 2007, Elsevier

    Professor Pancras C.W. Hogendoorn

  191. Sarcoma Derived from Cultured Mesenchymal Stem Cells

    Article • Stem Cells, October 2006, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  192. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies

    Article • Nuclear Medicine and Biology, October 2006, Elsevier

    Dr. Mick Welling, Professor Pancras C.W. Hogendoorn

  193. Pathology of primary malignant bone and cartilage tumours

    Article • International Orthopaedics, August 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  194. Chondroid lipoma: findings on radiography and MRI (2006:7b)

    Article • European Radiology, August 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  195. Array‐comparative genomic hybridization of central chondrosarcoma

    Article • Cancer, July 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  196. Giant cell tumors of the tendon sheath may present radiologically as intrinsic osseous lesions

    Article • European Radiology, June 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  197. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling

    Article • The Journal of Pathology, June 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  198. Nora’s lesion, a distinct radiological entity?

    Article • Skeletal Radiology, April 2006, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  199. Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines

    Article • Cancer Genetics and Cytogenetics, April 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  200. Clinico-histologic parameters of osteosarcoma patients with late relapse

    Article • European Journal of Cancer, March 2006, Elsevier

    Mr Matthew R Sydes, Professor Pancras C.W. Hogendoorn

  201. Soft tissue pathology

    Article • Current Diagnostic Pathology, February 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  202. Brachyury and chordoma: the chondroid–chordoid dilemma resolved?

    Article • The Journal of Pathology, January 2006, Wiley

    Professor Pancras C.W. Hogendoorn

  203. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model

    Article • Modern Pathology, January 2006, Elsevier

    Professor Pancras C.W. Hogendoorn

  204. Central high-grade osteosarcoma of bone: Diagnostic and genetic considerations

    Article • Current Diagnostic Pathology, December 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  205. Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study

    Article • European Journal of Cancer, December 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  206. Limited Rescue of Osteoclast‐Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor

    Article • Journal of Bone and Mineral Research, December 2005, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  207. Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma

    Article • Clinical Cancer Research, November 2005, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  208. TGF‐β1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone

    Article • The Journal of Pathology, November 2005, Wiley

    Professor Pancras C.W. Hogendoorn

  209. Accuracy of radiography in grading and tissue-specific diagnosis—a study of 200 consecutive bone tumors of the hand

    Article • Skeletal Radiology, October 2005, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  210. Desmoplastic fibroma of bone: an immunohistochemical study including -catenin expression and mutational analysis for -catenin

    Article • Human Pathology, September 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  211. Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials G...

    Article • Journal of Clinical Oncology, August 2005, American Society of Clinical Oncology (ASCO)

    Professor Pancras C.W. Hogendoorn

  212. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment

    Article • The Lancet Oncology, August 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  213. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade

    Article • The Journal of Pathology, July 2005, Wiley

    Professor Pancras C.W. Hogendoorn

  214. Corrections to “Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO”

    Article • Annals of Oncology, June 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  215. Consensus meeting for the management of gastrointestinal stromal tumors
 Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Article • Annals of Oncology, April 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  216. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis

    Article • The Journal of Experimental Medicine, March 2005, Rockefeller University Press

    Professor Pancras C.W. Hogendoorn

  217. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting

    Article • Virchows Archiv, March 2005, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  218. Chondromyxoid fibroma resemblesin vitro chondrogenesis, but differs in expression of signalling molecules

    Article • The Journal of Pathology, January 2005, Wiley

    Paul HC Eilers, Professor Pancras C.W. Hogendoorn

  219. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study

    Article • European Journal of Cancer, January 2005, Elsevier

    Professor Pancras C.W. Hogendoorn

  220. Mutation screening of EXT1 and EXT2 by direct sequence analysis and MLPA in patients with multiple osteochondromas: splice site mutations and exonic deletions account for more than half of the mutations

    Article • European Journal of Human Genetics, December 2004, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  221. Aggressive angiomyxoma: a clinicopathological and immunohistochemical study of 11 cases with long-term follow-up

    Article • Virchows Archiv, November 2004, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  222. Primary synovial sarcoma of the heart: a cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH of a case with a complex karyotype

    Article • Modern Pathology, November 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  223. Soft-Tissue Tumors: Value of Static and Dynamic Gadopentetate Dimeglumine–enhanced MR Imaging in Prediction of Malignancy

    Article • Radiology, November 2004, Radiological Society of North America (RSNA)

    Professor Pancras C.W. Hogendoorn

  224. Magnetic resonance imaging of knee cartilage using a water selective balanced steady‐state free precession sequence

    Article • Journal of Magnetic Resonance Imaging, October 2004, Wiley

    Professor Pancras C.W. Hogendoorn

  225. Multicolor fluorescence in situ hybridization analysis of a synovial sarcoma of the larynx with a t(X;18)(p11.2;q11.2) and trisomies 2 and 8

    Article • Cancer Genetics and Cytogenetics, August 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  226. A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours

    Article • European Journal of Cancer, June 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  227. Solitary fibrous tumour: the emerging clinicopathologic spectrum of an entity and its differential diagnosis

    Article • Current Diagnostic Pathology, June 2004, Elsevier

    Professor Pancras C.W. Hogendoorn

  228. Expression Profiling of t(12;22) Positive Clear Cell Sarcoma of Soft Tissue Cell Lines Reveals Characteristic Up-Regulation of Potential New Marker Genes Including ERBB3

    Article • Cancer Research, May 2004, American Association for Cancer Research (AACR)

    Professor Pancras C.W. Hogendoorn

  229. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families

    Article • Oncogene, April 2004, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  230. Chondroma and chondrosarcoma of the larynx

    Article • Current Opinion in Otolaryngology & Head & Neck Surgery, April 2004, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  231. Dedifferentiated Adamantinoma With Revertant Mesenchymal Phenotype

    Article • The American Journal of Surgical Pathology, December 2003, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  232. SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology

    Article • The Journal of Pathology, September 2003, Wiley

    Professor Pancras C.W. Hogendoorn

  233. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

    Article • European Journal of Cancer, September 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  234. Pathology of soft tissue sarcomas with emphasis on molecular diagnostic techniques

    Article • European Journal of Cancer Supplements, September 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  235. Langerhans-cell histiocytosis: neoplasia or unbridled inflammation?

    Article • Trends in Immunology, August 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  236. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma

    Article • European Journal of Human Genetics, July 2003, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  237. G2M arrest, blocked apoptosis, and low growth fraction may explain indolent behavior of head and neck paragangliomas

    Article • Human Pathology, July 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  238. Aberrant Chemokine Receptor Expression and Chemokine Production by Langerhans Cells Underlies the Pathogenesis of Langerhans Cell Histiocytosis

    Article • The Journal of Experimental Medicine, May 2003, Rockefeller University Press

    Professor Pancras C.W. Hogendoorn

  239. Langerhans-cell histiocytosis 'insight into DC biology'

    Article • Trends in Immunology, April 2003, Elsevier

    Professor Pancras C.W. Hogendoorn

  240. Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results

    Article • European Radiology, January 2003, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  241. Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma

    Article • Cancer Genetics and Cytogenetics, December 2002, Elsevier

    Professor Pancras C.W. Hogendoorn

  242. Clear cell sarcoma of the stomach

    Article • Histopathology, December 2002, Wiley

    Professor Pancras C.W. Hogendoorn

  243. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup

    Article • European Journal of Cancer, June 2002, Elsevier

    Professor Pancras C.W. Hogendoorn

  244. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

    Article • European Journal of Cancer, March 2002, Elsevier

    Professor Pancras C.W. Hogendoorn

  245. Diffusion‐weighted MRI in the characterization of soft‐tissue tumors

    Article • Journal of Magnetic Resonance Imaging, February 2002, Wiley

    Professor Pancras C.W. Hogendoorn

  246. Chromosome 9 Alterations and Trisomy 22 in Central Chondrosarcoma: A Cytogenetic and DNA Flow Cytometric Analysis of Chondrosarcoma Subtypes

    Article • Diagnostic Molecular Pathology, December 2001, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  247. Retain or sacrifice the posterior cruciate ligament in total knee arthroplasty? A histopathological study of the cruciate ligament in osteoarthritic and rheumatoid disease

    Article • Journal of Clinical Pathology, May 2001, BMJ

    Professor Pancras C.W. Hogendoorn

  248. Synovial sarcoma: dynamic contrast-enhanced MR imaging features

    Article • Skeletal Radiology, February 2001, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  249. Adamantinoma-like Ewing's sarcoma and Ewing's-like adamantinoma. The t(11; 22), t(21; 22) status

    Article • The Journal of Pathology, January 2001, Wiley

    Professor Pancras C.W. Hogendoorn

  250. Infantile‐type digital fibromatosis tumour in an adult

    Article • British Journal of Dermatology, November 2000, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  251. Malignant progression in multiple enchondromatosis (Ollier's disease): An autopsy-based molecular genetic study

    Article • Human Pathology, October 2000, Elsevier

    Professor Pancras C.W. Hogendoorn

  252. An update of diagnostic strategies using molecular genetic and magnetic resonance imaging techniques for musculoskeletal tumors

    Article • Current Opinion in Rheumatology, January 2000, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  253. EXT-Mutation Analysis and Loss of Heterozygosity in Sporadic and Hereditary Osteochondromas and Secondary Chondrosarcomas

    Article • The American Journal of Human Genetics, September 1999, Elsevier

    Professor Pancras C.W. Hogendoorn

  254. Ring Chromosome 4 as the Sole Cytogenetic Anomaly in a Chondroblastoma

    Article • Cancer Genetics and Cytogenetics, September 1998, Elsevier

    Professor Pancras C.W. Hogendoorn

  255. Maligne Knorpeltumoren

    Article • Der Radiologe, June 1998, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  256. Chondroblastic osteosarcoma: characterisation by gadolinium-enhanced MR imaging correlated with histopathology

    Article • Skeletal Radiology, March 1998, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  257. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities

    Article • Skeletal Radiology, February 1998, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  258. How is the mutational status for tumor suppressors p53 and p16INK4A in MFH of the bone?

    Article • Cancer Letters, January 1998, Elsevier

    Professor Pancras C.W. Hogendoorn

  259. MR imaging based strategies in limb salvage surgery for osteosarcoma of the distal femur

    Article • Skeletal Radiology, November 1997, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  260. Cytogenetic analysis of adamantinoma of long bones: Further indications for a common histogenesis with osteofibrous dysplasia

    Article • Cancer Genetics and Cytogenetics, August 1997, Elsevier

    Professor Pancras C.W. Hogendoorn

  261. Skin Metastases of Osteogenic Sarcoma

    Article • Journal of Pediatric Hematology/Oncology, May 1997, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  262. Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous-to-epithelial transformation

    Article • Human Pathology, February 1997, Elsevier

    Professor Pancras C.W. Hogendoorn

  263. Molecular Identification of a Partial Hydatidiform Mole

    Article • Diagnostic Molecular Pathology, February 1997, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  264. Calcified meningioma of the skull base simulating chondrosarcoma

    Article • European Journal of Radiology, December 1995, Elsevier

    Professor Pancras C.W. Hogendoorn

  265. Translocation Identification of an Ews-Pseudogene Using Detection by RT-PCR in Ewings-Sarcoma

    Article • Biochemical and Biophysical Research Communications, August 1995, Elsevier

    Professor Pancras C.W. Hogendoorn

  266. Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?

    Article • Clinical Radiology, June 1995, Elsevier

    Professor Pancras C.W. Hogendoorn

  267. Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging

    Article • Skeletal Radiology, October 1994, Springer Science + Business Media

    Professor Pancras C.W. Hogendoorn

  268. Metastasis of Breast Carcinoma to a Primary Mucinous Cystadenocarcinoma of the Ovary

    Article • Gynecologic Oncology, January 1994, Elsevier

    Professor Pancras C.W. Hogendoorn

  269. Adamantinoma of the Long Bones: Keratin Subclass Immunoreactivity Pattern with Reference to Its Histogenesis

    Article • The American Journal of Surgical Pathology, December 1993, Wolters Kluwer Health

    Professor Pancras C.W. Hogendoorn

  270. Antigen size influences the type of glomerular pathology in chronic serum sickness

    Article • Nephrology Dialysis Transplantation, January 1993, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn

  271. Unusual Manifestations of Yersinia enterocolitica Infections Diagnosed Using Novel Methods

    Article • Clinical Infectious Diseases, October 1992, Oxford University Press (OUP)

    Professor Pancras C.W. Hogendoorn